Document Detail


Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
MedLine Citation:
PMID:  25433360     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency to treat patients with relapsed and/or refractory multiple myeloma (RRMM). This agent is an effective treatment for this challenging population, but proteasome inhibition has the potential for significant cardiac toxicity via the accumulation of intracellular protein aggregates. Although large clinical trials have not suggested an excess of heart failure (HF) with PI therapy, animal studies and case reports in humans with the PI bortezomib have suggested otherwise. We describe the clinical presentation and management of six patients with RRMM who experienced significant cardiac toxicity associated with carfilzomib treatment. A common clinical syndrome of dyspnea associated with left ventricular systolic and/or diastolic dysfunction was identified. These abnormalities were largely reversible with prompt cessation of PI therapy and initiation of traditional heart failure treatments. Safe re-administration of carfilzomib with dose modification was possible in some cases.
Authors:
Wilson Grandin; Bonnie Ky; R Frank Cornell; Joseph Carver; Daniel J Lenihan
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-26
Journal Detail:
Title:  Journal of cardiac failure     Volume:  -     ISSN:  1532-8414     ISO Abbreviation:  J. Card. Fail.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-29     Completed Date:  -     Revised Date:  2014-11-30    
Medline Journal Info:
Nlm Unique ID:  9442138     Medline TA:  J Card Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Subjective Social Status in select Ukrainians, Vietnamese, and Mongolians living in the Czech Republ...
Next Document:  Heart Transplantation vs Continuous Flow LVAD: Comprehensive Cost at One Year.